JGC
NEOS

J. Goldman & Co’s Neos Therapeutics, Inc NEOS Stock Holding History

J. Goldman & Co’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-120,000
Closed -$313K – 376
2019
Q1 		$313K Sell
120,000
-546,000
-82% -$1.28M 0.02% 248
2018
Q4 		$1.1M Sell
666,000
-995,420
-60% -$2.79M 0.08% 176
2018
Q3 		$8.06M Sell
1,661,420
-56,563
-3% -$321K 0.56% 55
2018
Q2 		$10.7M Buy
1,717,983
+478,983
+39% +$3.57M 0.55% 52
2018
Q1 		$10.3M Buy
1,239,000
+589,000
+91% +$5.62M 0.44% 57
2017
Q4 		$6.63M Buy
650,000
+14,135
+2% +$136K 0.35% 85
2017
Q3 		$5.82M Sell
635,865
-209,135
-25% -$1.59M 0.29% 96
2017
Q2 		$6.17M Buy
+845,000
New +$6.38M 0.33% 88

Other funds holding NEOS

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's NEOS Position: Q2 2019 in Review

J. Goldman & Co sold out of Neos Therapeutics, Inc (NEOS) in Q2 2019, closing a stake of 120,000 shares — an estimated $313K sold.

J. Goldman & Co first reported a position in NEOS in Q2 2017 and held it in 8 quarters. The position peaked at $10.7M in Q2 2018. 58 funds tracked by Wall St. Rank hold NEOS as of Q2 2019.

  • J. Goldman & Co reported no remaining Neos Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • J. Goldman & Co sold 120,000 Neos Therapeutics, Inc shares in Q2 2019, an estimated $313K.
  • J. Goldman & Co first reported a position in Neos Therapeutics, Inc in Q2 2017 and held it in 8 quarters.
  • J. Goldman & Co's Neos Therapeutics, Inc position peaked at $10.7M in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q2 2019.

Based on J. Goldman & Co's 13F filing for Q2 2019, filed 14 Aug 2019.